Clasp Therapeutics Stock
Clasp Therapeutics is developing T cell receptor (TCR)-based immunotherapies designed to treat solid tumors. Its approach combines targeted antigen recognition with proprietary immune cell engineering to enhance the specificity and efficacy of T cell therapies against cancer.
For more Clasp Therapeutics stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Robert Ross, MD Chief Executive Officer |
| James B. Bingham, PhD Chief Technology Officer |
